Friday, 16 October 2026European Markets

EDP And MAGNORA Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(VIANEWS) - EDP (EDP.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Utilities sector.

Financial Asset Price Forward Dividend Yield Return on Equity
EDP (EDP.LS) €3.71 4.65% 8.28%
MAGNORA (MGN.OL) kr33.95 0.55% 59.67%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. EDP (EDP.LS)

4.65% Forward Dividend Yield and 8.28% Return On Equity

EDP - Energias de Portugal, S.A. engages in the generation, transmission, distribution, and supply of electricity in Portugal, Spain, France, Poland, Romania, Italy, Belgium, the United Kingdom, Greece, Colombia, Brazil, North America, and internationally. It operates through Renewables, Networks, and Client Solutions & Energy Management segments. The company primarily generates and sells electricity through hydro, CCGT, coal, wind, solar, nuclear, and cogeneration and waste sources. It has an installed capacity of 28 GW; and operates 380,788 kilometers of distribution network lines. The company is also involved in the supply of natural gas. In addition, it offers engineering, laboratory tests, professional training, and energy services, as well as property management services. The company's electricity and gas customers include domestic, industrial, commercial, agricultural, and others. EDP - Energias de Portugal, S.A. was incorporated in 1976 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, EDP has a trailing twelve months EPS of €0.19.

PE Ratio

EDP has a trailing twelve months price to earnings ratio of 19.5. Meaning, the purchaser of the share is investing €19.5 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.28%.

Sales Growth

EDP's sales growth is negative 13.7% for the ongoing quarter and 157.7% for the next.

More news about EDP.

2. MAGNORA (MGN.OL)

0.55% Forward Dividend Yield and 59.67% Return On Equity

Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr4.01.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 8.47. Meaning, the purchaser of the share is investing kr8.47 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 59.67%.

More news about MAGNORA.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com